| Identification | Back Directory | [Name]
N-[[4-[(Hydroxyamino)carbonyl]phenyl]methyl]-2-(4-methoxyphenyl)-4-pyridinecarboxamide | [CAS]
2716217-79-5 | [Synonyms]
HDAC-IN-57
N-[[4-[(Hydroxyamino)carbonyl]phenyl]methyl]-2-(4-methoxyphenyl)-4-pyridinecarboxamide | [Molecular Formula]
C21H19N3O4 | [MOL File]
2716217-79-5.mol | [Molecular Weight]
377.39 |
| Hazard Information | Back Directory | [Uses]
HDAC-IN-57 is an orally active inhibitor of histone deacetylases (HDAC), with IC50s of 2.07 nM, 4.71 nM, 2.4 nM and 107 nM for HDAC1, HDAC2, HDAC6, HDAC8, respectively. HDAC-IN-57 can inhibits LSD1, with IC50 of 1.34 μΜ. HDAC-IN-57 induces apoptosis, and has anti-tumor activity[1]. | [IC 50]
HDAC1: 2.07 nM (IC50); HDAC2: 4.71 nM (IC50); HDAC6: 2.4 nM (IC50); HDAC8: 107 nM (IC50) | [References]
[1] Duan Y, et al. Discovery of novel, potent, and orally bioavailable HDACs inhibitors with LSD1 inhibitory activity for the treatment of solid tumors. Eur J Med Chem. 2023 Jun 5;254:115367. DOI:10.1016/j.ejmech.2023.115367 |
|
|